2015 main events in drug therapy


The year 2015 was marked with the outstanding advances in clinical evaluation of scientific discoveries made during previous period. During this year new data on significant clinical activity of check-point inhibitors in various tumors was obtained. These drugs were shown to be effective in NSCLC, breast cancer, melanoma and MSI associated malignancies. New significant advances were made in the development of consecutive generations of TKI’s for activating mutations addicted tumors. Furthermore, new design of clinical trials facilitating the research of clinical efficacy of new targeted drugs in cancers associated with rare activating mutations emerged. The current review is aimed to describe these advances.